This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Bremelanotide improved sexual desire and reduced distress in 1202 patients across most subgroups.
Why it matters
This research provides evidence that bremelanotide can effectively treat HSDD in various demographics, potentially improving quality of life for many women.
How the study worked
The study involved 1202 patients who self-administered bremelanotide 1.75 mg or a placebo for 24 weeks, with efficacy measured using specific sexual function scales.
What this study cannot tell us
The study may not fully represent all women with HSDD, and results from clinical trials may not always translate to real-world settings.
Read the original research
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Journal of women's health (2002), 31(3), 391-400
Citation
Simon, James A; Kingsberg, Sheryl A; Portman, David; Jordan, Robert; Lucas, Johna; Sadiq, Amama; Krop, Julie; Clayton, Anita H. (2022). Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.. Journal of women's health (2002), 31(3), 391-400. https://doi.org/10.1089/jwh.2021.0225